Cellectis S.A.
CMVLF
$1.25
-$0.25-16.67%
| Weiss Ratings | CMVLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | CMVLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CMVLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.09 | |||
| Price History | CMVLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 0.00% | |||
| 60-Day Total Return | -50.79% | |||
| 90-Day Total Return | -50.79% | |||
| Year to Date Total Return | 0.00% | |||
| 1-Year Total Return | -46.81% | |||
| 2-Year Total Return | -47.92% | |||
| 3-Year Total Return | -66.58% | |||
| 5-Year Total Return | -92.15% | |||
| 52-Week High % Change | -57.77% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | CMVLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.96 | |||
| 52-Week Low Price | $1.25 | |||
| 52-Week Low Price (Date) | Jan 02, 2025 | |||
| 52-Week High Price (Date) | May 16, 2024 | |||
| Valuation | CMVLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 129.85M | |||
| Enterprise Value | 62.98M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.32 | |||
| Earnings Per Share Growth | -22.28% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 3.47 | |||
| Price/Book (Q) | 0.97 | |||
| Enterprise Value/Revenue (TTM) | 3.13 | |||
| Price | $1.25 | |||
| Enterprise Value/EBITDA (TTM) | -1.68 | |||
| Enterprise Value/EBIT | -1.45 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | CMVLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 100.09M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CMVLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 33 1 81 69 16 00 | |||
| Address | -- | |||
| Website | www.cellectis.com | |||
| Country | France | |||
| Year Founded | 1999 | |||
| Profitability | CMVLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -216.28% | |||
| Profit Margin | -237.34% | |||
| Management Effectiveness | CMVLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -16.09% | |||
| Return on Equity | -- | |||
| Income Statement | CMVLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 29.07M | |||
| Total Revenue (TTM) | 36.04M | |||
| Revenue Per Share | $0.36 | |||
| Gross Profit (TTM) | 35.88M | |||
| EBITDA (TTM) | -67.22M | |||
| EBIT (TTM) | -77.96M | |||
| Net Income (TTM) | -85.55M | |||
| Net Income Avl. to Common (TTM) | -85.55M | |||
| Total Revenue Growth (Q YOY) | 997.99% | |||
| Earnings Growth (Q YOY) | -31.88% | |||
| EPS Diluted (TTM) | -1.32 | |||
| EPS Diluted Growth (Q YOY) | 26.77% | |||
| Balance Sheet | CMVLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 159.09M | |||
| Cash Per Share (Q) | $1.59 | |||
| Total Current Assets (Q) | 294.43M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 129.42M | |||
| Current Ratio (Q) | 1.777 | |||
| Book Value Per Share (Q) | $1.29 | |||
| Total Assets (Q) | 395.88M | |||
| Total Current Liabilities (Q) | 165.65M | |||
| Total Debt (Q) | 89.87M | |||
| Total Liabilities (Q) | 266.45M | |||
| Total Common Equity (Q) | 129.42M | |||
| Cash Flow | CMVLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -99.80M | |||
| Cash from Financing (TTM) | 127.77M | |||
| Net Change in Cash (TTM) | 91.73M | |||
| Levered Free Cash Flow (TTM) | -14.78M | |||
| Cash from Operations (TTM) | 62.75M | |||
